Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 MilestonesGlobeNewsWire • 01/06/23
Ultragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corporate UpdateGlobeNewsWire • 10/27/22
Earnings Preview: Ultragenyx (RARE) Q3 Earnings Expected to DeclineZacks Investment Research • 10/25/22
Kyowa Kirin Receives European Commission Approval for Use of CRYSVITA®▼(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)Business Wire • 08/19/22
Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate UpdateGlobeNewsWire • 07/28/22
Ultragenyx to Host Conference Call for Second Quarter 2022 Financial Results and Corporate UpdateGlobeNewsWire • 07/25/22
Ultragenyx Shares Tumble On Initial Efficacy Missing Expectations, This Analyst Sees 'Viable Path Forward"Benzinga • 07/19/22
Ultragenyx and GeneTx Provide Program Update on GTX-102 for Angelman Syndrome Including Promising Interim Data from Phase 1/2 StudyGlobeNewsWire • 07/18/22
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $500 Million to OMERS Capital MarketsGlobeNewsWire • 07/14/22
Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA® ▼(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)Business Wire • 06/24/22